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ABSTRACT 
Adverse drug reactions are the undesirable unintended response of the drug which occurs at the doses normally used for the 
diagnosis, prophylaxis and treatment of the patient. ADR is the harmful effect other than desirable or expected which can vary from 
desirable from mild to severe reaction, even sometimes responsible for causing considerable morbidity and mortality. The reasons 
include overdose, polypharmacy, diseased condition etc. to name few among them. The increased ADR rate is highly alarming and 
thus requires proper monitoring and reporting of ADR to the concerned regulatory authorities. In this review we try to cover 
different aspects of adverse drug reactions like its types, factors affecting ADR, reasons for increasing rate of ADR, preventive 
measures and also the monitoring and reporting of ADR. 
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INTRODUCTION 
An adverse drug reaction (ADR) can be defined as ‘an 
appreciably harmful or unpleasant reaction resulting 
from an intervention related to the use of a medicinal 
product; adverse effects usually predict hazard from 
future administration and warrant prevention, or specific 
treatment, or alteration of the dosage regimen, or 
withdrawal of the product’.1 
World Health Organization defines ADRs as ‘a 
response to medicine which is noxious and unintended, 
and which occurs at doses normally used in man for the 
prophylaxis, diagnosis, or therapy of disease or for the 
modification of physiological function’ 2 
 “A harmful or significantly unpleasant effect caused by 
a drug at doses intended for therapeutic effect (or 
prophylaxis or diagnosis) which warrants reduction of 
dose or withdrawal of the drug and/or foretells hazard 
from future administration.”3 
The Joint Commission on the Accreditation of 
Healthcare Organisations (JCAHO) defines an 
adverse drug reaction (ADR) as an undesired effect of a 
medication that either increases toxicity, decreases 
desired therapeutic effect, or both 
4,5,6
 
As per Edwards ADR is an appreciably harmful or 
unpleasant reaction, caused by an intervention related to 
the use of a medicinal product, which predicts hazard 
from future administration and warrants prevention or 
specific treatment, or alteration of the dosage regimen, 
or withdrawal of the product.
6,7
 
As defined by ASHP Adverse drug reaction is an 
unexpected, unintended, undesired, or excessive 
response to a drug that requires discontinuing the drug 
(therapeutic or diagnostic), enquires changing the drug 
therapy, requires modifying the dose (except for minor 
dosage adjustments), necessitates admission to a 
hospital, prolongs stay in a health care facility, 
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necessitates supportive treatment, significantly 
complicates diagnosis, negatively affects prognosis, or 
results in temporary or permanent harm, disability, or 
death)
7
 
TYPES OF ADVERSE DRUG REACTIONS 
3,7,8
 
1. Augmented or dose related 
2. Bizarre or Non dose related 
3. Dose and time related 
4. Time related 
5. Withdrawal 
6. Failure of therapy 
 
1. Augmented: Most common and major cause of 
ADR. It is related to the pharmacological action of 
drug. It is dose dependent and the level of severity 
increases with increase in dose. Its occurrence can 
be limited by slow introduction of low dosages. 
Predictable by the pharmacological mechanisms, 
e.g., dry mouth with tricyclic antidepressants and 
respiratory depression with opoids. 
2. Bizarre: It is rare, not related to pharmacologic 
action of drug, also unrelated to the dose, 
unpredictable, mechanisms are unknown. It can be 
fatal resulting in high mortality, e.g. aplastic 
anaemia caused by chloramphenicol, neuroleptic 
malignant hyperthermia caused by some general 
anaesthetics and antipsychotics. Management 
includes withholding the drug avoidance in future.  
3. Dose and Time Related: Occurs as a result of 
continuous drug use i.e. cumulative dose. It is 
umcommon, unexpected & unpredictable, e.g. 
tardive dyskinesias by antipsychotics, dementia by 
anticholinergic medications, osteonecrosis of the 
jaw with bisphosphonates 
4. Time Related: Delayed occurrence of ADRs, 
Occurs or becomes apparent sometime after use of 
the drug even after the cessation of treatment e.g., 
corneal opacities after thioridazine, ophthalmopathy 
after chloroquine, leucopenia with lomustine. 
5. Withdrawal: Withdrawal reactions which are 
uncommon and occur soon after the withdrawal. 
Management includes reintroducing the drug and 
withdrawing it slowly. Occurs typically with the 
depressant drugs, e.g., hypertension and restlessness 
in opiate abstainer; insomnia and anxiety with 
benzodiazapenes. 
6. Failure of Therapy: It is common in occurrence, 
related to dose of drug and interactions between the 
drugs are the major reason of this type of ADR. 
Management includes consideration of 
simultaneous drug therapy. 
ADVERSE DRUG EVENT 
7
 
Any unexpected occurrence that may occur during 
treatment with a pharmaceutical product but that does 
not necessarily have a causal relation to the drug in use. 
WHY IS THE FREQUENCY OF ADR’S 
ALARMING?
4
 
There are several reasons to which it can be attributed, 
which include:  
1) Polypharmacy; simultaneous administration of 
various drugs at same time for an individual’s 
patient.  
2) Patient non adherence, healthcare provider’s 
workloads, unfamiliarity or ignorance to ADR’s and 
communication failures.  
3) The ever-increasing number of new drugs in the 
market; and, 
4) Insufficient attention to identify adverse drug 
reactions 
5) The lack of a defined and systematic approach for 
monitoring of adverse drug reactions   
PREDISPOSING/ SUSCEPTIBILITY FACTORS 
TO ADVERSE DRUG REACTIONS 
7,9,10,11
 
They can be categorised as: 
1. Patient related factors 
2. Drug related factors 
3. Disease related factors 
4. Social factors 
Drug Related Factors 
1. Drug dose, frequency and Time of 
Administration: Administering under dose or over 
dose of medication, increasing or decreasing 
frequency of administration, changing the 
appropriate time of the day to administer the 
medication can cause patient harmful drug effects. 
2. Poly-pharmacy: It may cause ADRs due to the 
drug additive effect, synergism, duplication, drug 
interactions, discontinuation of treatment and 
physiological antagonism. 
Patient Related Factors 
1. Age: Paediatrics and geriatrics. These categories of 
patients are not usually studied extensively during 
clinical trials. Geriatric patients with multiple 
disease conditions, decreased drug elimination and 
previous history of allergy are more prone to ADRs. 
However, paediatric patients have low capacity to 
metabolize drug hence more prone to ADRs. 
2. Sex: Men differ from women in GIT motility also 
have higher body weight, internal organ size and 
glomerular filtration but lesser body fat; these 
factors affect both the drug pharmacokinetics and 
pharmacodynamics. Menstruation, pregnancy and 
menopause are peculiar to women; their occurrence 
may significantly affect drug actions. 
3. Pregnancy: During pregnancy several 
physiological changes occur which may affect drug 
pharmacokinetics as well as pharmacodynamics; 
these include cardiovascular changes; increase in 
cardiac output (32%) due to the increase in heart 
rate (10-15bmp) and increase in stroke volume; 
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increase in blood volume (1500-1800ml); increase 
in renal drug excretion due to increase in renal 
blood flow (30%), increase in GFR (50%) and 
decrease in serum protein (1-1.5) .GIT motility, 
acidity and tone increase during pregnancy which 
leads to changes in drug absorption, excretion and 
metabolism .During pregnancy ADRs may affect 
only the mother, the foetus or both. 
4. Renal function:  Kidney disease alters rate of drug 
clearance and metabolism leading to drug toxicity 
and low therapeutic effect which can be diagnosed 
by level of creatinine clearance. 
Disease Related Factors 
Drug that is useful in treatment of one disease may be 
harmful in others; using NSAIDS to treat pain may 
exacerbate peptic ulcer; also condition of patient with 
asthma may worsen if he is treated with propranolol for 
angina or hypertension. Patients with chronic diseases 
like diabetes, high or low blood pressure, ulcer, 
glaucoma, an enlarge prostate, poor bladder control 
should be monitored carefully, because such categories 
of patients are more prone to drug-disease interaction 
and ADRs. 
Social Factors 
1. Smoking: Smoking induce liver cytochrome P450 
iso-enzymes CYP1A1, 1A2 and possibly 2E2 
leading to the increase in metabolism of drugs that 
are substrate to these group of enzyme and decrease 
their pharmacological action Studies revealed that 
cigarette smoking decrease the action of β-blockers 
on blood pressure. Smoking also interacts with 
drugs like theophylline, thiothixene, insulin, oral 
contraceptives, and H2 blockers. Clinical 
investigation proves that on average, insulin 
dependent diabetic smoker needed 15-20% more 
insulin than non-smokers, and up to 30% more for 
heavy smokers. 
2. Alcohol:  affect drug metabolism and promote 
development of ADRs. Alcohol causes hepatitis and 
liver cirrhosis that significantly affect the rate of 
drug metabolism; liver disease is proved to increase 
the toxicity of β-blockers. Concurrent ingestion of 
alcohol with some drugs has led to many ADRs like 
nausea, vomiting, headache, drowsiness, fainting, 
and hypotension. 
3. Race: Occurrence of ADRs differs from one 
population of patients to another due to genetic 
differences Patient from East-Asia have three times 
risk of developing cough with ACE inhibitors than 
white patients. Research has shown that black 
people had higher risk of intracranial haemorrhage 
and also had 3.0 relative risk of angioedema 
compared to non-black people. 
PREVENTING ADVERSE DRUG REACTIONS 
8
 
These steps can help in preventing the occurrence of 
adverse drug reaction: 
1.  Identification of the group of individuals who are 
probably more susceptible to the adverse effect and 
accordingly the modification in the treatment plan. 
2. Ensuring that the treatment plan alleviates any 
possible adverse effects. 
Identifying Susceptibility 
A patient's medication history helps in identifying any 
previous ADRs and therefore prevents re-exposure to 
the drug. Patient’s susceptibility accordingly helps in 
making the decision for prescribing the right drug of 
choice. As discussed earlier number of factors affects 
the susceptibility such as age, gender, pregnancy status 
and racism can help predict the risk of an ADR 
occurrence.  
Treatment Plan 
Judicious and safe prescribing plays an important role in 
reducing errors that can contribute to ADRs. Treatment 
plans should consider and mitigate for any possible 
adverse effects. For example, co-prescription of folic 
acid with methotrexate will reduce the incidence of 
adverse effects associated with folate deficiency; and 
monitoring electrolytes and renal function when treating 
with renally active drugs or diuretics. These examples 
can all prevent treatment-emergent adverse effects 
although may be limited because monitoring 
recommendations are often inadequate or ambiguous.  
POPULATIONS AT GREATER RISK 
7,10,11
 
1. Paediatrics 
2. Geriatrics 
3. Patients with renal and hepatic impairment 
4. Genetic Variations 
 
Pediatrics: Infants and very young children are more 
susceptible or at a greater risk of ADR since their 
capacity to metabolize the drug is not fully developed. 
Neonates have immature renal tubular function below 8 
weeks thus NSAIDS are necessarily required to be 
avoided. Physiologic hypoalbuminemia affects drug 
dosing. The body fat content is very low and thus the 
effect of fat soluble drugs is also reduced. Immature 
blood brain barrier till 8 weeks after birth is also linked 
to the increased anesthetic effect. Predisposition to 
hypotension due to poor cardiac compliance. 
Geriatrics: The probability or susceptibility of adverse 
drug reaction is twice in elderly people.  The major type 
of ADR affecting in elderly is Type A i.e. more than 
85%. Various reasons justify the statement.  
 One reason which can be attributed to this is several 
health issues affecting at the same time which 
requires them to take several prescription and over 
the counter medications, which ultimately enhances 
the chances of ADR. 
 Secondly liver looses ability to metabolize the 
drugs. 
 Water in the body decreases; i.e fat to water content 
increases. This condition requires the lower dose of 
drug which dissolves in water since due to less 
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water it will produce higher concentration in the 
body, increasing the susceptibility of ADR. 
 Kidneys are less able to excrete drugs into urine. 
Due to decrease in the efficiency of various body organs 
and various other facts drugs tend to stay much longer in 
the body prolonging drugs effect and increase the risk of 
side effects and adverse drug reactions 
Patients with renal and hepatic impairment: Liver 
and kidney are the major organs for the metabolism and 
excretion for mostly all the drugs. Impairment of any of 
these can affect the drug absorption, metabolism, 
distribution, clearance and ultimately the bioavailability 
of various drugs. In patients with renal failure, the effect 
of drugs on the kidneys is lessened because of the loss 
of the site of action for these drugs. This leads to 
increasing the dose which in turn leads to more ADRs. 
One of the important ways is to monitor the laboratory 
values and adjustments in drug dosage can ultimately 
prevent an adverse drug reaction using these metabolic 
and excretory pathways. 
ADR Monitoring 
7,12
 
The first step in identifying ADRs can be performed 
actively or passively. 
Active surveillance: It involves interviewing patients 
and physicians in a sample of healthcare centres called 
sentinel sites and also the review of medical history or 
medical records.. A follow-up questionnaire can be sent 
to each prescribing physician or the patient at specified 
intervals to obtain information. In the event of data 
monitoring, patients may either be identified from 
electronic prescription data or automated health 
insurance claims. Another way is to opt registries which 
are a list of patients presenting similar characteristic(s). 
This characteristic can be a disease (disease registry) or 
a specific exposure (drug registry). The potential 
information can be collected using standardized 
questionnaires; for example, pregnancy exposure 
registries for products that are likely to be used during 
pregnancy.  
Another method of ADR monitoring is through 
clinicians; for example, requesting them for a feedback 
(for a certain period of time) after the introduction of a 
new drug in the market or in hospital settings. 
Passive Surveillance: The passive methods comprise 
spontaneous reports and case series of similar reports. A 
spontaneous report is a voluntary communication by 
healthcare professionals (doctors, including dentists, 
nurses and pharmacists) to a industry, regulatory body 
or an organization (e.g. WHO regional centres, poison 
control centres) that describes one or more ADRs in a 
patient who was administered one or more medicinal 
products. This report is not derived from a study or any 
organized data-collection scheme. The data 
accompanying spontaneous reports are often 
incomplete. But these reports play a major role in the 
identification of safety signals once a drug is marketed. 
For instance, temafloxacin, a fluoroquinolone antibiotic, 
was withdrawn within six months of its introduction 
because of the association between its use and 
haemolytic anaemia in otherwise healthy individuals. 
Spontaneous reporting rapidly identified this ADR 
because it was rare in the general population and 
occurred within one week of drug use.  
Assessing causality between drugs and suspected 
reactions 
2,3,7,12
 
To derive the relationship between a drug and adverse 
reaction(s), causality assessment is important tool. There 
is no gold standard for this assessment. Some of the 
commonly used scales are Naranjo’s scale, WHO 
probability scale, European ABO system, Kramer’s 
scale, Bayesian system, Karch and Lasagna scale, and 
French imputation method7. The categorization of 
causal relationships between a drug and the suspected 
adverse reactions varies with the scale adopted. As per 
WHO scale the causality relationships are categorized 
into certain, probable, possible, 
unassessible/unclassifiable, unlikely, and 
conditional/unclassifiable, whereas as per Naranjo scale 
it is categorized as definite, probable, possible or 
unlikely.  
Commonly, the following four aspects should be 
considered while allocating a clinical adverse event to a 
drug:  
(i) Time related relationship between the suspected 
reaction and the drug;  
(ii) Dechallenge (Termination of drug); 
(iii) Rechallenge (reintroduction of drug), and 
(iv)  Probability of other possible causes. 
Reporting adverse drug reactions
12
 
The National Pharmacovigilance Programme (NPP) 
encourages the reporting of all suspected drug-related 
adverse events, including those suspected to have been 
caused by herbal, traditional and alternative remedies 
Notifying seemingly insignificant or common adverse 
reactions would be important as it may highlight 
widespread prescribing problems. The programme 
particularly solicits reports of: 
(i) All adverse events suspected to have been caused by 
new drugs and ‘drugs of current interest’ 
(ii) All suspected drug interactions and 
(iii) Reactions to any other drugs that are suspected of 
significantly affecting a patient's management, including 
death, life-threatening conditions (risk of death), 
hospitalization (initial or prolonged), disability 
(significant, persistent or permanent) and congenital 
anomaly. Here intervention is required to prevent 
permanent impairment or damage.  
TIME DURATION TO REPORT SUSAR’S 12 
The specified time duration for reporting of fatal or life-
threatening suspected unexpected serious adverse 
reactions (SUSARs) is not later than seven days after the 
sponsor had information that the case fulfilled the 
necessary criteria; any follow- up information is to be 
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provided within a further period of eight days. All other 
SUSARs are to be notified not later than fifteen days.  
REGULATORY AUTORITIES FOR REPORTING 
OF ADVERSE DRUG REACTIONS 
12
 
The various ADR regulatory authorities are 
1. Committee on Safety of Medicine, 
2. Adverse Drug Reactions Advisory Committee, 
3. MedWatch and Vaccine Adverse Event Reporting 
System. 
4. The WHO–Uppsala Monitoring Committee (UMC) 
international database in Sweden     maintains all 
information on ADRs. 
5. In India, NPP located at the Central Drugs Standard 
Control Organization (CDSCO), in New Delhi 
Two zonal centres: All India Institute of Medical 
Sciences, New Delhi for north and east & King Edward 
Memorial Hospital, Mumbai for south and west  
Five regional centres:  
1. Department of Pharmacology, JIPMER 
Pondicherry. 
2. TN Medical College, Mumbai. 
3.  IGMC Nagpur. 
4.  Lady Harding Medical College, New Delhi. 
5. NRS Medical College, Kolkata. 
24 peripheral centres: including some medical colleges 
and hospitals approved by the Medical Council of India, 
private hospitals, public health programmes and 
autonomous institutes. 
The ADR form is available at any pharmacovigilance 
centre .The completed form should be sent to the 
peripheral pharmacovigilance centre or in case of 
doubts, it can be sent directly to CDSCO. The 
information provided is handled in strict confidence. 
The peripheral centre forwards the submitted form to the 
regional centre where causality analysis is carried out, 
after which it is sent to the zonal centre. The data are 
statistically analysed and forwarded to WHO–UMC.
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